These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38062163)

  • 1. Impact of three miRNA signature as potential diagnostic marker for triple negative breast cancer patients.
    Kumar V; Gautam M; Chaudhary A; Chaurasia B
    Sci Rep; 2023 Dec; 13(1):21643. PubMed ID: 38062163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
    Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
    PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of dysregulated microRNAs associated with diagnosis and prognosis in triple‑negative breast cancer: An in silico study.
    Fan C; Liu N
    Oncol Rep; 2019 Jun; 41(6):3313-3324. PubMed ID: 30942465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.
    Hong HC; Chuang CH; Huang WC; Weng SL; Chen CH; Chang KH; Liao KW; Huang HD
    Theranostics; 2020; 10(19):8771-8789. PubMed ID: 32754277
    [No Abstract]   [Full Text] [Related]  

  • 5. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing.
    Chen YL; Wang K; Xie F; Zhuo ZL; Liu C; Yang Y; Wang S; Zhao XT
    Clin Chim Acta; 2022 Jun; 531():302-308. PubMed ID: 35504321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
    Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of dysregulated miRNAs in triple negative breast cancer: A meta-analysis approach.
    Naorem LD; Muthaiyan M; Venkatesan A
    J Cell Physiol; 2019 Jul; 234(7):11768-11779. PubMed ID: 30488443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
    Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
    BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer.
    Yang R; Xing L; Wang M; Chi H; Zhang L; Chen J
    Cell Physiol Biochem; 2018; 50(2):473-488. PubMed ID: 30308479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
    Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K
    Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miRNA-135b Contributes to
    Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
    Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer.
    Zhao Y; Song Y; Zhang Y; Ji M; Hou P; Sui F
    Mol Cell Probes; 2023 Dec; 72():101940. PubMed ID: 37871689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of microRNAs in triple-negative breast cancer.
    Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I
    Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down Regulated Expression Levels of miR-27b and miR-451a as a Potential Biomarker for Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy.
    Abdul Aziz AA; Md Salleh MS; Yahya MM; Zakaria AD; Ankathil R
    Asian Pac J Cancer Prev; 2022 Mar; 23(3):1053-1059. PubMed ID: 35345380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Potential Long Non-Coding RNA Candidates that Contribute to Triple-Negative Breast Cancer in Humans through Computational Approach.
    Rahman MM; Hossain MT; Reza MS; Peng Y; Feng S; Wei Y
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer.
    Tang H; Huang X; Wang J; Yang L; Kong Y; Gao G; Zhang L; Chen ZS; Xie X
    Mol Cancer; 2019 Feb; 18(1):23. PubMed ID: 30744636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.